Scholars@Duke publication: Supplementary Figure S5 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models

Supplementary Figure S5 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models

Publication , Other

Ma, J; Hegde, S; Sergeeva, M; Chakraborty, B; Wardell, SE; McDonnell, DP; Huang, PQ; Bunker, KD; Doñate, F; Lackner, MR; Samatar, AA

April 2, 2026

Published version (DOI) Publisher Link

<p>Supplementary Figure S5 shows ZN-c5 activity in ERY537S tumors. A. Key ER downstream targets expression by qPCR in WT or ERY537S heterozygous cells. B. ER downstream target GREB expression by qPCR in WT or ERY537S heterozygous cells after treatment with 0.1nM E2, 100nM ZN-c5 or 100nM fulvestrant. C. Western blot analysis of ER and PR protein after different concentrations of ZN-c5 treatment for the indicated time in MCF7 ERY537S heterozygous cells. ER or PR protein change (%) relative to non-treatment control after correction by GAPDH. D. WHIM20 tumor bearing mice were dosed with ZN-c5 or fulvestrant at PR protein level in WHIM20 tumor samples harvested at the end of an efficacy study. ZN-c5 was dosed at 40mg/kg, fulvestrant was dosed at 5mg/dose. E. ER expression in WHIM20 tumors by immunohistochemistry (IHC) at the end of efficacy study</p>

Duke Scholars

Author Binita Chakraborty

Author Suzanne E Wardell Pharmacology & Cancer Biology

Author Donald Patrick McDonnell Pharmacology & Cancer Biology

DOI

10.1158/1535-7163.31923574

Publication Date

April 2, 2026

Citation

APA

Chicago

ICMJE

MLA

NLM

Ma, J., Hegde, S., Sergeeva, M., Chakraborty, B., Wardell, S. E., McDonnell, D. P., … Samatar, A. A. (2026). Supplementary Figure S5 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models. https://doi.org/10.1158/1535-7163.31923574

Ma, Jianhui, Sayee Hegde, Masha Sergeeva, Binita Chakraborty, Suzanne E. Wardell, Donald P. McDonnell, Peter Q. Huang, et al. “Supplementary Figure S5 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models,” April 2, 2026. https://doi.org/10.1158/1535-7163.31923574.

Ma J, Hegde S, Sergeeva M, Chakraborty B, Wardell SE, McDonnell DP, et al. Supplementary Figure S5 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models. 2026.

Ma, Jianhui, et al. Supplementary Figure S5 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models. 2 Apr. 2026. Crossref, doi:10.1158/1535-7163.31923574.

Ma J, Hegde S, Sergeeva M, Chakraborty B, Wardell SE, McDonnell DP, Huang PQ, Bunker KD, Doñate F, Lackner MR, Samatar AA. Supplementary Figure S5 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models. 2026.

DOI

10.1158/1535-7163.31923574

Publication Date

April 2, 2026